SAB Biotherapeutics, Inc. (SABS) Stock Forecast
SABS analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.91 / 5 from 11 analysts
- Price target
- $11.64 average of analyst targets
- Upside to target
- +359.9% from the latest close
- Next earnings
- November 13, 2026 EPS estimate $-0.27
- 52-week range
- $2.49 – $4.59
SABS analyst ratings
11 analystsNumber of analysts at each rating.
SABS price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
SABS earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.27 | −$0.32 | −$0.22 | — | — | 5 |
| Current fiscal year (2026) | −$1.16 | −$1.34 | −$1.04 | −$0.81 | −44.1% | 5 |
| Next fiscal year (2027) | −$0.95 | −$1.22 | −$0.60 | −$1.16 | +17.9% | 5 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
SABS revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 8 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 8 |
| Next fiscal year (2027) | $62,500 | $0 | $500,000 | 0.0% | 8 |
SABS EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
SABS revenue: reported and forecast
SABS EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.00 | −$0.24 | −$0.30 | −$0.30 | −$0.27 | — | 2 up · 0 down |
| Current fiscal year (2026) | −$0.30 | −$1.08 | −$1.28 | −$1.28 | −$1.16 | +287.5% | 1 up · 0 down |
| Next fiscal year (2027) | −$0.33 | −$0.89 | −$0.98 | −$0.98 | −$0.95 | +189.2% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
SABS earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; SABS beat in 6 of 12.
What analysts expect from SABS
11 analysts cover SAB Biotherapeutics; their consensus rating is strong buy (4.91 on a 1–5 scale, where 5 is a strong buy). The average price target is $11.64, 359.9% above the latest close of $2.53. Analysts expect earnings of −$1.16 per share for 2026, −44.1% from a year earlier. For 2027 the average estimate is −$0.95 per share on revenue of $0.1 million. SAB Biotherapeutics beat the EPS estimate in 6 of the last 12 quarters.
Related: SABS income statement, SABS key metrics, SABS chart. See the SABS stock overview for the latest quote and news.
SABS forecast FAQ
What is SAB Biotherapeutics's price target?
The average analyst price target for SAB Biotherapeutics is $11.64, 359.9% above the latest close of $2.53.
Is SAB Biotherapeutics a buy, hold or sell?
Of 11 analysts covering SAB Biotherapeutics, 10 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is SAB Biotherapeutics's EPS forecast?
Analysts forecast −$1.16 per share for 2026 (range −$1.34 to −$1.04); for 2027 the estimate is −$0.95.
When does SAB Biotherapeutics report earnings?
SAB Biotherapeutics is expected to report results for the quarter ending September 30, 2026 on November 13, 2026; the EPS estimate is $-0.27.
Does SAB Biotherapeutics usually beat earnings estimates?
SAB Biotherapeutics reported EPS at or above the analyst estimate in 6 of the last 12 quarters.